ATH434 — FDA meeting
mid - 2026
Phase 3 Trial Planning Ongoing with FDA End - of - Phase 2 expected in mid - 2026Source filing
ATHE biotech catalysts & pipeline
ALTERITY THERAPEUTICS LTD · Data as of 2026-09-08
ALTERITY THERAPEUTICS LTD · Data as of 2026-09-08
mid - 2026
Phase 3 Trial Planning Ongoing with FDA End - of - Phase 2 expected in mid - 2026Source filing